Uveal melanoma
MONDO:0006486A melanoma derived from melanocytes of the uveal tract. It is the most common primary intraocular tumor in the United States and Western Europe. Similar to melanoma of the skin, it is rare in Africa and Asia. Diagnostic procedures include ophthalmoscopic exam, fluorescein angiography and ultrasound. Treatment includes: surgical excision of the eye, iridocyclectomy and tumor resection. Recent treatments also include radiotherapy or photo coagulation. Classification of uveal melanomas recognizes four cell types within these tumors: epithelioid, intermediate, mixed cell, and spindle cell types. The spindle cell type uveal melanomas are further sub-classified as spindle cell type A and spindle cell type B.
Also known as: intraocular melanoma, melanoma (disease) of uvea, melanoma of the uvea, melanoma of uvea, melanoma, uveal, malignant, uvea melanoma, uvea melanoma (disease), uveal melanoma
2929 clinical trials for this condition and its sub-types, 98 tagged with Uveal melanoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Uveal melanoma
-
Malignant choroid melanoma 10 trials
5 sub-types
- Choroid epithelioid cell melanoma 0 trials
- Choroid mixed cell melanoma 0 trials
- Choroid necrotic melanoma 0 trials
- Choroid spindle cell melanoma 0 trials
- Intermediate cell type choroid melanoma 0 trials
-
Iris melanoma 4 trials
3 sub-types
- Intermediate cell type iris melanoma 0 trials Sub-types →
- Iris spindle cell melanoma 0 trials Sub-types →
- Malignant ciliary body melanoma 0 trials Sub-types →
-
Posterior uveal melanoma 0 trials · 3 incl. sub-types
2 sub-types
-
Epithelioid cell uveal melanoma 0 trials
2 sub-types
- Choroid epithelioid cell melanoma 0 trials
- Ciliary body epithelioid cell melanoma 0 trials
-
2 sub-types
-
Mixed cell uveal melanoma 0 trials
2 sub-types
- Choroid mixed cell melanoma 0 trials
- Ciliary body mixed cell melanoma 0 trials
-
Necrotic uveal melanoma 0 trials
1 sub-type
- Choroid necrotic melanoma 0 trials
-
Spindle cell intraocular melanoma 0 trials
2 sub-types
- Choroid spindle cell melanoma 0 trials
- Iris spindle cell melanoma 0 trials Sub-types →
Most studied deeper sub-types
-
Liver-Targeted immune cell attack tested against melanoma spread
Disease control Not yet recruitingResearchers are testing a treatment for melanoma that has spread to the liver. They collect tumor-infiltrating lymphocytes, a type of immune cell, from the patient's own tumor and grow them in the lab. Before returning the cells, they use a technique called percutaneous hepatic p…
Phase 1 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Immune cells injected into liver or veins to fight advanced melanoma
Disease control Not yet recruitingThis early-stage trial tests whether immune cells taken from a patient's own tumor (TIL) can be safely given directly into the liver or through a vein to fight metastatic melanoma. 18 adults with advanced uveal or cutaneous melanoma that has spread will receive TIL along with che…
Phase 1 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a single eye injection shrink melanoma and save sight?
Disease control Not yet recruitingThis early-phase trial is testing an investigational drug called RBP-01 (sotrastaurin), given as an injection into the eye, for people with primary uveal melanoma—a rare cancer of the eye. The study aims to see if the drug is safe and whether it can shrink the tumor enough to avo…
Phase 1/2 • Sponsor: ReBio Pharma • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
A steroid premedication may tame the immune reaction to a melanoma therapy
Prevention Not yet recruitingThis phase 2 trial tests whether a low dose of the steroid dexamethasone, given before the first four infusions of tebentafusp, can prevent cytokine release syndrome in people with advanced uveal melanoma. Tebentafusp is a standard first-line treatment for this eye cancer, but it…
Phase 2 • Sponsor: University of California, San Diego • Aim: Prevention
Last updated Sep 05, 2026 00:00 UTC